Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Syntara Limited ( (AU:SNT) ) is now available.
Syntara Limited has announced the commencement of the MDS05/D3 MESSAGE Phase 2 clinical trial in Australia, evaluating the drug amsulostat in combination with a hypomethylating agent for patients with transfusion-dependent, low and intermediate risk Myelodysplastic Syndromes (MDS). This trial, led by the Australasian Leukaemia & Lymphoma Group and funded by the Australian Government’s Medical Research Future Fund, aims to reduce the need for frequent blood transfusions and improve survival outcomes for MDS patients. The trial’s initiation represents a significant step in Syntara’s strategy to expand its treatment options for blood cancer patients, potentially enhancing the quality of life for those with limited treatment alternatives.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company focusing on innovative treatments for blood cancers. The company is involved in developing amsulostat, a drug aimed at treating various hematological conditions, including myelofibrosis and myelodysplastic syndromes (MDS).
Average Trading Volume: 2,634,040
Technical Sentiment Signal: Sell
Current Market Cap: A$47.34M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.